Court Sets Hearing Date for Diomed Preliminary Injunction Against Total Vein Solutions

  
    
  
  
    
      Diomed Holdings, Inc. (AMEX: DIO - News), a leading developer and 
      marketer of minimally invasive medical technologies, including its 
      patented EndoVenous Laser Treatment (EVLT(R)) for varicose veins, today 
      announced that the court has set January 18, 2008 as the date to hear 
      Diomed’s request for a preliminary injunction 
      against Total Vein Solutions in its continuing efforts to enforce its 
      U.S. Patent Number 6,398,777 covering the endovascular laser treatment 
      of varicose veins.
    
    
      Diomed commenced legal action in the U.S. Federal District Court for the 
      District of Massachusetts against Total Vein Solutions seeking 
      injunctive relief and damages for infringement of Diomed's '777 patent 
      in 2004. In a separate 2006 hearing against defendants AngioDynamics, 
      Inc. and Vascular Solutions, Inc., Judge Gorton of the same Federal 
      District Court ruled that Diomed's '777 patent is both valid and 
      enforceable. In the trial ending on March 28, 2007, the jury found the 
      defendants liable for both inducing infringement and contributory 
      infringement of Diomed's patent. Judge Gorton subsequently granted 
      Diomed a permanent injunction against both defendants and awarded Diomed 
      a total of $14.7 million in damages.
    
    
      "We have been pleased with the court’s 
      previous rulings which prohibit two of our competitors from selling 
      their infringing lasers and disposable products," said James A. Wylie, 
      President and CEO of Diomed. "Now that the court has found Diomed's 
      patent to be valid and enforceable and a jury has found competing 
      contact-based laser fiber systems to infringe, we believe that an 
      immediate injunction of Total Vein Solutions' sales of such infringing 
      products would be timely and appropriate."
    
    
      About Diomed
    
    
      Diomed develops and commercializes minimal and micro-invasive medical 
      procedures that use its proprietary laser technologies and disposable 
      products. Diomed's EVLT(R) laser vein ablation procedure is used in 
      varicose vein treatments. Diomed also provides photodynamic therapy 
      (PDT) for use in cancer treatments, and dental and general surgical 
      applications. The EVLT(R) procedure and the Company's related products 
      were cleared by the United States FDA in January of 2002. Along with 
      lasers and single-use procedure kits for its EVLT(R) laser vein 
      treatment, the Company provides its customers with state of the art 
      physician training and practice development support. Additional 
      information is available on the Company's website: www.evlt.com.
    
    
      EVLT(R) is a registered trademark of Diomed Inc., Andover, MA.
    
    
      Safe Harbor
    
    
      Safe Harbor statements under the Private Securities Litigation Reform 
      Act of 1995: Statements in this news release looking forward in time 
      involve risks and uncertainties, including the risks associated with 
      trends in the products markets, reliance on third party distributors in 
      various countries outside the United States, reoccurring orders under 
      OEM contracts, market acceptance risks, technical development risks and 
      other risk factors. These statements relate to our future plans, 
      objectives, expectations and intentions. These statements may be 
      identified by the use of words such as "may," "will," "should," 
      "potential," "expects," "anticipates," "intends," "plans," "believes" 
      and similar expressions. These statements are based on our current 
      beliefs, expectations and assumptions and are subject to a number of 
      risks and uncertainties. Our actual results could differ materially from 
      those discussed in these statements. Our 2006 Annual Report on Form SEC 
      10-KSB (the "Annual Report") contains a discussion of certain of the 
      risks and uncertainties that affect our business. We refer you to the 
      "Risk Factors" on pages 19 through 34 of the Annual Report for a 
      discussion of certain risks, including those relating to our business as 
      a medical device company without a significant operating record and with 
      operating losses, our risks relating to our commercialization of our 
      current and future products and applications and risks relating to our 
      common stock and its market value. Diomed disclaims any obligation or 
      duty to update or correct any of its forward-looking statements.